FDA Rejects Proposed Chronic Kidney Disease Indication for VytorinForbesIn SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease (CKD), and major vascular events were reduced in the treatment group c…
Region's First FDA Approved Long-Term Heart Pump at Albany Med – HealthCanal.com
WNYTRegion's First FDA Approved Long-Term Heart Pump at Albany MedHealthCanal.comAlbany, NY,- David Morey, 63, of Guilderland, was released from Albany Medical Center yesterday after having received the region's first HeartMate II mechanical he…
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in … – MarketWatch (press release)
Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in …MarketWatch (press release)"CMX001 in the Peri-Engraftment Period Does Not Impair Neutrophil Recovery in Pediatric Allogeneic Hematopoietic Stem Cell Recipients," w…
James Farentino dies of heart failure at 73 – New York Daily News
New York Daily NewsJames Farentino dies of heart failure at 73New York Daily NewsThe official cause was heart failure. A family spokesman said he had been ill for some time. Farentino was best known for his long recurring role on "Dynasty," b…
Good response to blood donation – New Straits Times
New Straits TimesGood response to blood donationNew Straits TimesPANTAI Hospital Kuala Lumpur (PHKL) and Pantai Premier Pathology jointly organised a blood donation campaign with National Blood Centre recently. A donor is all smiles as she contributes …
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® – Business Wire (press release)
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN®Business Wire (press release)Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated…
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN(R) – MarketWatch (press release)
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN(R)MarketWatch (press release)Deaths have occurred within 24 hours of rituximab infusion, an essential component of the ZEVALIN therapeutic regimen. These fatalities were associated …
Organ donor target 'will not be met' – Glasgow Evening Times
The GuardianOrgan donor target 'will not be met'Glasgow Evening TimesBy CAROLINE WILSON A TARGET to boost organ donor rates by 50% by 2013 in the UK will not be met, charity leaders have warned. Tim Statham, chief executive of the National Kidn…
Approval of first-ever medicine for rare blood vessels diseases offers hope … – Canada NewsWire (press release)
Approval of first-ever medicine for rare blood vessels diseases offers hope …Canada NewsWire (press release)1 Today, Roche announced that RITUXAN ® (rituximab), in combination with glucocorticoids, is the first medicine approved by Health Canada for…
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth … – MarketWatch (press release)
Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth …MarketWatch (press release)Presented New Daclizumab Data at Multiple Sclerosis Congress Announced with our partner company Biogen Idec additional results from the SELECT Phase 2…